Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track KPTI with free AI briefings, catalyst countdowns, and dilution alerts.

KPTI · Karyopharm Therapeutics Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

Chapter 11 bankruptcy. Karyopharm Therapeutics filed for Chapter 11 bankruptcy protection on Nov 3, 2026 (8-K, Item 1.03). Read the filing
$65.1M Cash on Hand
8.2mo Cash Runway
Follow KPTI by email Get an email when KPTI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about KPTI, unsubscribe in one click. Privacy

📣 What KPTI Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Selinexor (KPT-330)
FDA approved Jul 2019 · Xpovio
Multiple Myeloma Phase 3 · NCT05028348 Active not recruiting
Mezigdomide Multiple Myeloma Phase 1/2 · NCT02343042 Recruiting
Eltanexor (KPT-8602) Relapsed/Refractory Multiple Myeloma (RRMM) Phase 1/2 · NCT02649790 Completed
Tipiracil Metastatic Colorectal Cancer Phase 2 · NCT04854434 Terminated
Enasidenib Relapsed Refractory Multiple Myeloma Phase 1/2 · NCT03732703 Completed
Bendamustine Relapsed or Refractory Diffuse Large B-Cell Lymphoma Phase 1/2 · NCT04607772 Withdrawn
Decitabine and Cedazuridine (ASTX727) Relapsed/Refractory Multiple Myeloma (RRMM) Phase 1/2 · NCT02649790 Completed
Imlunestrant Low Grade Ovarian Serous Adenocarcinoma Phase 2 · NCT07832227 Not yet recruiting
FOLFIRI Non-Small Cell Lung Carcinoma (NSCLC) Phase 1/2 · NCT04256707 Completed
Padnarsertib (KPT-9274) Acute Myeloid Leukemia Phase 1 · NCT04914845 Completed
Methylprednisolone Refractory Multiple Myeloma Phase 1 · NCT04519476 Unknown
Niacin ER Solid Tumors Phase 1 · NCT02702492 Terminated
Fludarabine Acute Leukemia of Ambiguous Lineage in Relapse Phase 1 · NCT04898894 Active not recruiting

Also used in these trials (approved or third-party drugs, not KPTI's own candidates): Cisplatin, Elotuzumab, Pomalidomide, Dexamethasone, Rituximab, Ruxolitinib, Bortezomib, Gemcitabine Hydrochloride, Oxaliplatin, Paclitaxel, Pacritinib, Momelotinib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

KPTI holds $65.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $23.8M/quarter from operations, an estimated runway of 8.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 80 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when KPTI files for a raise →

👥 Who Owns KPTI

Insiders 3.6% Institutions (143 holders) 96.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
RA Capital Management, L.P. Institution (13G, 5%+) 2,517,362 11.10% 2026-09-30
Adage Capital Management, L.P. Institution (13G, 5%+) 2,013,106 8.88% 2026-09-30
Affinity Asset Advisors, LLC Institution (13G, 5%+) 1,573,517 6.94% 2026-09-30
T. Rowe Price Investment Management, Inc Institution (13G, 5%+) 1,539,147 6.79% 2026-05-31
BlackRock, Inc. Institution (13G, 5%+) 1,266,084 5.58% 2026-06-30
Richard A. Paulson
President and CEO, Director
Insider 269,747 1.19% 2026-05-13
Sohanya Roshan Cheng
EVP & Chief Commercial Officer
Insider 107,940 0.48% 2026-05-13
Stuart Poulton
EVP, Chief Development Officer
Insider 94,632 0.42% 2026-07-28
Michael Mano
EVP, CLO&Secretary
Insider 94,398 0.42% 2026-05-13
Lori Macomber
EVP, CFO & Treasurer
Insider 85,105 0.38% 2026-02-03
Reshma Rangwala
EVP & Chief Medical Officer
Insider 56,829 0.25% 2026-05-13
Kristin Abate
Chief Accounting Officer
Insider 18,616 0.08% 2026-10-16

Share count 22,681,460 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full KPTI picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KPTI and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.